- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01181713
Change in Ocular Flora Resistance From Repeated Topical Antibiotic Use
Antibiotic Resistance of Ocular Surface Flora After Continued Use of Topical Antibiotics Post Intravitreal Injections
Study Overview
Status
Detailed Description
Treatment with intravitreal (IVT) injections has increased during the last several years as evidence has accumulated demonstrating the efficacy of anti-vascular endothelial growth factor agents in the treatment of neovascular age-related macular degeneration (AMD) and various retinal vascular diseases.
Although IVT injections are generally safe, infectious endophthalmitis is a rare but devastating complication, and the risk of morbidity and vision loss from endophthalmitis is high. The objective is to examine the change in antibiotic resistance of ocular surface flora with repeated prophylactic use of antibiotics after IVT injection for AMD.
Yin, V. T., Weisbrod, D. J., Eng, K. T., Schwartz, C., Kohly, R., Mandelcorn, E., Lam, W., Daneman, N., Simor, A., & Kertes, P. J. (2013). Antibiotic resistance of ocular surface flora with repeated use of a topical antibiotic after intravitreal injection. JAMA ophthalmology, 131(4), 456-461.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health and Sciences Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients scheduled for intravitreal injection for neovascular age-related macular degeneration (ARMD)
- 65 years or older
- able to provide informed consent.
Exclusion Criteria:
- diagnosed with an active ocular, periocular or systemic infection
- previously received treatment with an intravitreal injection
- previously treated with antibiotics in the past three months
- unable to attend the scheduled follow-up appointments or to complete treatment for any reason
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
No Antibiotic
No prophylactic antibiotic post intravitreal injection
|
Prophylactic Antibiotic
Group treated with 3 day course of prophylactic topic antibiotic, fourth generation fluoroquinolones, after each intravitreal injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ocular flora resistance to 4th generation fluoroquinolone
Time Frame: 1 year
|
Outcome will examine the change in amount, type and antibiotic resistance profile of ocular surface flora over the 3 months.
Charcoal swab of the conjunctiva will be cultured, organisms grown will be identified and resistance to moxifloxacin will be quantified by minimal inhibitory resistance (MIC).
|
1 year
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Peter Kertes, MD, FRCSC, Sunnybrook Health Sciences Centre
- Study Director: Vivian T Yin, MD, University of Toronto
- Study Director: Daniel Weisbrod, MD, FRCSC, Sunnybrook Health Sciences Centre
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- SBK-OcuFResis
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Increased Drug Resistance
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingIncreased Drug Resistance | Resistance Bacterial | Drug Resistance, MicrobialBangladesh
-
Medstar Health Research InstituteUnknownIncreased Drug ResistanceUnited States
-
National OncoVentureHanmi Pharmaceutical Company LimitedCompletedIncreased Drug ResistanceKorea, Republic of
-
University of RochesterGlaxoSmithKline; Cornell University; American College of Clinical PharmacyCompleted
-
Hospital Departamental de VillavicencioCooperative University of ColombiaNot yet recruiting
-
University of Colorado, DenverAgency for Healthcare Research and Quality (AHRQ)CompletedInfectious Diseases | Increased Drug ResistanceUnited States
-
Assiut UniversityCompleted
-
Department of Medical Research, Lower MyanmarKangwon National UniversityCompletedMalaria | Increased Drug Resistance | Asymptomatic Infection
-
Population Health Research InstituteCompleted
-
Human Biome Institute S.A.RecruitingAntimicrobial Drug Resistance | Drug Resistance, BacterialPoland